Sponsors / ARWR
ARWR

Arrowhead Pharmaceuticals

Company identity has not yet been verified

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
22Trials in this database
23Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) InfectionNCT02065336Arrowhead PharmaceuticalsPhase 2Terminated2017-01Actual
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B VirusNCT02452528Arrowhead PharmaceuticalsPhase 2Terminated2016-12Actual
Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)NCT02577029Arrowhead PharmaceuticalsPhase 2Terminated2016-12Actual
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) InfectionNCT02604199Arrowhead PharmaceuticalsPhase 2Terminated2017-01Actual
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus InfectionNCT02604212Arrowhead PharmaceuticalsPhase 2Terminated2016-12Actual
Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) InfectionNCT02738008Arrowhead PharmaceuticalsPhase 2Terminated2016-12Actual
Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)NCT03945292Arrowhead PharmaceuticalsPhase 2Completed2021-11-08Actual
Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)NCT03946449Arrowhead PharmaceuticalsPhase 2Completed2022-04-28Actual
Study to Evaluate ARO-APOC3 in Adults With Severe HypertriglyceridemiaNCT04720534Arrowhead PharmaceuticalsPhase 2Completed2023-03-09Actual
Study of ARO-ANG3 in Adults With Mixed DyslipidemiaNCT04832971Arrowhead PharmaceuticalsPhase 2Completed2022-08-30Actual
Study of Plozasiran (ARO-APOC3) in Adults With Mixed DyslipidemiaNCT04998201Arrowhead PharmaceuticalsPhase 2Completed2023-02-10Actual
Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)NCT05089084Arrowhead PharmaceuticalsPhase 3Completed2024-04-29Actual
Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)NCT05217667Arrowhead PharmaceuticalsPhase 2Terminated2023-05-02Actual
Study of ARO-APOC3 in Adults With DyslipidemiaNCT05413135Arrowhead PharmaceuticalsPhase 2Completed2025-09-22Actual
Study of Plozasiran (ARO-APOC3) in Adults With Severe HypertriglyceridemiaNCT06347003Arrowhead PharmaceuticalsPhase 3Active not recruiting2026-06-12Actual
Study of Plozasiran in Adults With Severe HypertriglyceridemiaNCT06347016Arrowhead PharmaceuticalsPhase 3Active not recruiting2026-06-17Actual
Phase 3 Study of Plozasiran in Adults With HypertriglyceridemiaNCT06347133Arrowhead PharmaceuticalsPhase 3Completed2026-06-01Actual
Long-Term Safety and Efficacy of Plozasiran in Adults With HypertriglyceridemiaNCT06822790Arrowhead PharmaceuticalsPhase 3Recruiting2028-07Estimated
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute PancreatitisNCT06880770Arrowhead PharmaceuticalsPhase 3Recruiting2029-03Estimated
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)NCT07037771Arrowhead PharmaceuticalsPhase 3Active not recruiting2027-08-20Estimated
Study of Inhaled ARO-RAGE in Allergen-induced Mild AsthmaNCT07241546Arrowhead PharmaceuticalsPhase 2Recruiting2027-12Estimated
Study of Zodasiran in Adolescent Participants With Homozygous Familial HypercholesterolemiaNCT07473843Arrowhead PharmaceuticalsPhase 3Not yet recruiting2028-07Estimated

Latest recorded trial changes

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

NCT07037771 · Arrowhead Pharmaceuticals

· 3 fields changed

Participant count type

Recorded edit
− Previous value

Estimated

+ Updated value

Actual

Enrollment · participant count

Recorded edit
− Previous value

count: 60; type: ESTIMATED

+ Updated value

count: 70; type: ACTUAL

Recruitment status

Recorded edit
− Previous value

Recruiting

+ Updated value

Active not recruiting

Check registry source
Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)

NCT05217667 · Arrowhead Pharmaceuticals

· 2 fields changed

Primary outcomes · main study measures

Text edit · unverified significance
− Previous value

measure: Percent Change from Baseline in Fasting Calculated Low-Density Lipoprotein-Cholesterol (LDL-C) and LDL-C by Preparative Ultracentrifugation (LDL-C [PUC]) up to Week 24

+ Updated value

measure: Percent Change From Baseline in Fasting LDL-C at Week 24

The saved outcome text may be shortened. Check the source for full wording.

Recruitment status

Recorded edit
− Previous value

Active not recruiting

+ Updated value

Terminated

Check registry source
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

NCT04720534 · Arrowhead Pharmaceuticals

· 1 field changed

Primary outcomes · main study measures

Text edit · unverified significance
− Previous value

measure: Percent Change from Baseline in Fasting Triglycerides (TG) at Week 24

+ Updated value

measure: Percent Change From Baseline at Week 24 in Fasting Triglycerides (TG)

The saved outcome text may be shortened. Check the source for full wording.

Check registry source
Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

NCT04998201 · Arrowhead Pharmaceuticals

· 1 field changed

Primary outcomes · main study measures

Text edit · unverified significance
− Previous value

measure: Percent Change from Baseline in Fasting Triglycerides (TG) at Week 24

+ Updated value

measure: Percent Change From Baseline at Week 24 in Fasting TG

The saved outcome text may be shortened. Check the source for full wording.

Check registry source
Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

NCT05089084 · Arrowhead Pharmaceuticals

· 1 field changed

Primary outcomes · main study measures

Text edit · unverified significance
− Previous value

measure: Percent Change from Baseline in Fasting Triglycerides (TG) at Month 10

+ Updated value

measure: Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG)

The saved outcome text may be shortened. Check the source for full wording.

Check registry source
Study of ARO-APOC3 in Adults With Dyslipidemia

NCT05413135 · Arrowhead Pharmaceuticals

· 3 fields changed

Completion date type

Recorded edit
− Previous value

Estimated

+ Updated value

Actual

Primary completion date

Recorded edit
− Previous value

2025-09

+ Updated value

2025-09-18

Recruitment status

Recorded edit
− Previous value

Active not recruiting

+ Updated value

Completed

Check registry source